The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

'Mad Money' host Jim Cramer weighs in on stock including: Lincoln Electric, Caesars Entertainment, CRISPR, and Seagate. This ...

What I've learned from my work in this field is that having a well-crafted commercial strategy is important for companies ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team ...